MedTrace Logo

Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions

NCT00936780 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2012-08-23

No results posted yet for this study

Summary

The primary objective of Infinnium-Core™ Registry is to assess the safety and efficacy of the Infinnium-Core™ Paclitaxel Eluting Coronary Stent System in de novo Coronary Lesions.

Conditions

Interventions

DEVICE

Infinnium-Core™ Paclitaxel eluting Coronary Stent

Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.

Sponsors & Collaborators

  • Sahajanand Medical Technologies Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936780 on ClinicalTrials.gov